MW Weight-loss-drug price war is on, as Wegovy prices cut for monthly subscribers
By Tomi Kilgore
Novo Nordisk's move for Wegovy users without insurance comes a week after a similar move from Eli Lilly for Zepbound
Novo Nordisk said game on, as the Denmark-based drugmaker lowered prices on its obesity treatment Wegovy for those without insurance, and said it would deliver the drug to their homes.
The company's $(NVO)$ move comes a week after Eli Lilly & Co. $(LLY)$ cut prices for its rival weight-loss drug Zepbound.
Novo Nordisk announced Wednesday the launch of NovoCare Pharmacy, which will offer all dose strengths of Wegovy for $499 a month, for patients without insurance or those with insurance that doesn't cover obesity drugs. The company noted that 90% of Wegovy users have coverage with copays of $0 to $25 a month.
The pharmacy will provide an option to have Wegovy delivered directly to the patient.
The new offering compares with a previous list price of $1,349 for a month's supply of Wegovy.
Novo Nordisk's U.S.-listed stock rallied 4.8% toward a three-month high in premarket trading Wednesday, while Eli Lilly shares edged up 0.3%.
Novo Nordisk's offer is different from Eli Lilly's, as Lilly said a 5-milligram dose of Zepbound would cost $499 a month, while 2.5-milligram doses would cost $349 a month.
The 7.5-milligram dose of Zepbound will cost $599 a month and the 10-milligram dose will cost $699 a month, or they will cost $499 a month at first fill or refills that occur within 45 days of the previous delivery.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
March 05, 2025 09:00 ET (14:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.